Animal-Derived Venom Compounds for Cancer Prevention and Intervention
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".
Deadline for manuscript submissions: 27 July 2026 | Viewed by 1151
Special Issue Editors
Interests: medicinal plants; bioactive compounds; phytochemicals; phytochemistry; cancer; metabolism; metabolic disorders; pharmacology; inflammation; oxidative stress; cardiovascular diseases; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Interests: inflammatory diseases; cardiovascular diseases; neurodegenerative diseases; inflammation; medicinal plants; oxidative stress
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Thank you for your time in reading this Special Issue introduction; it will be an honor to receive and assess your manuscript.
In recent years, several animal-derived venom compounds have demonstrated promising anticancer properties and have been studied for their potential in various preclinical and clinical settings against different malignancies. Often, they demonstrate the ability to induce apoptosis, inhibit angiogenesis, or target specific cancer-related critical molecular pathways associated with cancer growth and spread. In this regard, bufadienolide compounds from toad venom have been used against liver, lung, breast, and hematological cancers because they inhibit Na+/K+-ATPase and have anti-proliferative effects. Melittin from bee venom disrupts cancer cell membranes, limits angiogenesis, and induces apoptosis, effective against breast, leukemia, and liver cancers. Contortrostatin from snake venom disrupts integrins, promotes anti-angiogenic effects, and is effective against breast cancer. Many other examples exist, and many other compounds from animal venoms express different anticancer potential and mechanisms of action. Therefore, this Special Issue will delve into monitoring and testing these animal-derived venom compounds against cancer via preclinical and clinical studies. We will also accept systematic and critical reviews, including meta-analyses, for assessment and possible publication.
We look forward to receiving your feedback and valuable submissions; your participation in this Special Issue will be key to its success.
Dr. Lucas Fornari Laurindo
Dr. Sandra Barbalho
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- animal-derived venom anticancer agents
- cancer prevention and intervention
- functional venom products in oncology
- natural product oncology
- toxin-derived drugs
- bioactive peptides in cancer
- venom-based therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
